High expression of FAM64A also negatively affected OS and RFS among patients in with histological grade G1/G2 and clinical stage I/II cancers, but not with histological grade G3/G4 and clinical stage III/IV cancers, which further demonstrates the specific prognostic role of FAM64A expression in subgroup analysis and its potential contribution to precision therapy for pancreatic cancer. Here, PIMREG is linked to cancer.